Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5- dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4273-4288

  Casimiro Garcia, Agustin ^a   Piotrowski, David W ^a   Ambler, Catherine ^a   Arhancet, Graciela B ^a   Banker, Mary Ellen ^a   Banks, Tereece ^a   Boustany Kari, Carine M ^a   Cai, Cuiman ^a   Chen, Xiangyang ^a   Eudy, Rena ^a   Hepworth, David ^a   Hulford, Catherine A ^a   Jennings, Sandra M ^a   Loria, Paula M ^a   Meyers, Marvin J ^a   Petersen, Donna N ^a   Raheja, Neil K ^a   Sammons, Matthew ^a   She, Li ^a   Song, Kun ^a   Vrieze, Derek ^a   Wei, Liuqing ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 ETHOXYBENZOIC ACID; 4 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXYBENZOIC ACID; 4 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL]BENZOIC ACID; 4 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 Y] 2 METHOXYBENZOIC ACID; 6 [ 1 (5 CYANO 6 METHYL PYRIDIN 2 YL) 5 ISOPROPYL 4,5 DIHYDRO-1H PYRAZOL 3 YL] 2 METHOXYNICOTINIC ACID; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL) 2 ETHOXYNICOTINIC ACID; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N (1H TETRAZOL 5 YL)NICOTAMIDE; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N (METHYLSULFONYL)NICOTAMIDE; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N METHYLNICOTAMIDE; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N,N METHYLNICOTAMIDE; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXYNICOTAMIDE; 6 [1 (4 CYANO 3 METHYLPHENYL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXYNICOTINIC ACID; 6 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N (METHYLSULFONYL)NICOTAMIDE; 6 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N METHYLNICOTAMIDE; 6 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXY N,N DIMETHYLNICOTAMIDE; 6 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXYNICOTAMIDE; 6 [1 (5 CYANO 6 METHYLPYRIDIN 2 YL) 5 CYCLOPENTYL 4,5 DIHYDRO 1H PYRAZOL 3 YL] 2 METHOXYNICOTINIC ACID; CREATININE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; NICOTINIC ACID DERIVATIVE; PF 03882845; POTASSIUM; PROGESTERONE RECEPTOR; SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; POTASSIUM URINE LEVEL; RAT; SODIUM URINE LEVEL;

ANIMALS; DRUG DISCOVERY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MOLECULAR DOCKING SIMULATION; NICOTINIC ACIDS; POTASSIUM; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SODIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901265587     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500206r     Document Type: Article

References (54)

1. Lu, N. Z.; Wardell, S. E.; Burnstein, K. L.; Defranco, D.; Fuller, P. J.; Giguere, V.; Hochberg, R. B.; McKay, L.; Renoir, J.-M.; Weigel, N. L.; Wilson, E. M.; McDonnell, D. P.; Cidlowski, J. A. International union of pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors Pharmacol. Rev. 2006, 58, 782-797
2. Moore, J. T.; Collins, J. L.; Pearce, K. H. Nuclear receptor superfamily and drug discovery ChemMedChem 2006, 1, 504-523
3. Catena, C.; Colussi, G.; Marzano, L.; Sechi, L. A. Aldosterone and the heart: from basic research to clinical evidence Horm. Metab. Res. 2012, 44, 181-187
4. Fourkiotis, V. G.; Hanslik, G.; Hanusch, F.; Lepenies, J.; Quinkler, M. Aldosterone and the kidney Horm. Metab. Res. 2012, 44, 194-201
5. Lam, E. Y. M.; Funder, J. W.; Nikolic-Paterson, D. J.; Fuller, P. J.; Young, M. J. Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats Endocrinology 2006, 147, 3623-3629
6. Lieber, G. B.; Fernandez, X.; Mingo, G. G.; Jia, Y.; Caniga, M.; Gil, M. A.; Keshwani, S.; Woodhouse, J. D.; Cicmil, M.; Moy, L. Y.; Kelly, N.; Jimenez, J.; Crawley, Y.; Anthes, J. C.; Klappenbach, J.; Ma, Y.-L.; McLeod, R. L. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models Eur. J. Pharmacol. 2013, 718, 290-298
7. Hu, Q.; Yin, L.; Hartmann, R. W. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases. J. Med. Chem. 2014, DOI: dx.doi.org/10.1021/jm401430e.
8. Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl. J. Med. 1999, 341, 709-717
9. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 2003, 348, 1309-1321
10. Zannad, F.; McMurray, J. J. V.; Krum, H.; van, V. D. J.; Swedberg, K.; Shi, H.; Vincent, J.; Pocock, S. J.; Pitt, B. Eplerenone in patients with systolic heart failure and mild symptoms N. Engl. J. Med. 2011, 364, 11-21
11. Rossing, K.; Schjoedt, K. J.; Smidt, U. M.; Boomsma, F.; Parving, H.-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study Diabetes Care 2005, 28, 2106-2112
12. van, d. M. A. H.; Baggen, R. G.; Pauli, S.; Lindemans, A.; Vulto, A. G.; Poldermans, D.; Boomsma, F. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function J. Hypertens. 2006, 24, 2285-2292
13. Nielsen, S. E.; Persson, F.; Frandsen, E.; Sugaya, T.; Hess, G.; Zdunek, D.; Shjoedt, K. J.; Parving, H. H.; Rossing, P. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study Diabetic Med. 2012, 29, e184-e190
14. Esteghamati, A.; Noshad, S.; Jarrah, S.; Mousavizadeh, M.; Khoee, S. H.; Nakhjavani, M. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial Nephrol., Dial., Transplant. 2013, 28, 2823-2833
15. McManus, F.; McInnes, G. T.; Connell, J. M. C. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist Nature Clin. Pract. Endocrinol. Metab. 2008, 4, 44-52
16. Roscioni, S. S.; de, Z. D.; Bakker, S. J. L.; Lambers, H. H. J. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy Nature Rev. Nephrol. 2012, 8, 691-699
17. Piotrowski, D. W. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy J. Med. Chem. 2012, 55, 7957-7966
18. Baerfacker, L.; Kuhl, A.; Hillisch, A.; Grosser, R.; Figueroa-Perez, S.; Heckroth, H.; Nitsche, A.; Ergueden, J.-K.; Gielen-Haertwig, H.; Schlemmer, K.-H.; Mittendorf, J.; Paulsen, H.; Platzek, J.; Kolkhof, P. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases ChemMedChem 2012, 7, 1385-1403
19. Pitt, B.; Kober, L.; Ponikowski, P.; Gheorghiade, M.; Filippatos, G.; Krum, H.; Nowack, C.; Kolkhof, P.; Kim, S.-Y.; Zannad, F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial Eur. Heart J. 2013, 34, 2453-2463
20. Platt, D.; Pauli, H. Studies on organ- and subcellular distribution of 3H-spironolactone in animals Arzneim. Forsch. 1972, 22, 1801-1802
21. Kolkhof, P.; Borden, S. A. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics Mol. Cell. Endocrinol. 2012, 350, 310-317
22. Meyers, M. J.; Arhancet, G. B.; Chen, X.; Hockerman, S. L.; Long, S. A.; Mahoney, M. W.; Reitz, D. B.; Rico, J. G. Preparation of tetrahydro-2 H -benzo[ g ]indazole compounds as mineralocorticoid receptor antagonists. WO2008053300A1, 2008.
23. Dietz, J. D.; Du, S.; Bolten, C. W.; Payne, M. A.; Xia, C.; Blinn, J. R.; Funder, J. W.; Hu, X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 2008, 51, 742-748
24. Arhancet, G. B.; Woodard, S. S.; Dietz, J. D.; Garland, D. J.; Wagner, G. M.; Iyanar, K.; Collins, J. T.; Blinn, J. R.; Numann, R. E.; Hu, X.; Huang, H.-C. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines J. Med. Chem. 2010, 53, 4300-4304
25. Arhancet, G. B.; Woodard, S. S.; Iyanar, K.; Case, B. L.; Woerndle, R.; Dietz, J. D.; Garland, D. J.; Collins, J. T.; Payne, M. A.; Blinn, J. R.; Pomposiello, S. I.; Hu, X.; Heron, M. I.; Huang, H.-C.; Lee, L. F. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists J. Med. Chem. 2010, 53, 5970-5978
26. Arhancet, G. B.; Casimiro-Garcia, A.; Chen, X.; Hepworth, D.; Meyers, M. J.; Piotrowski, D. W.; Raheja, R. K. Preparation of 4,5-dihydro-1 H -pyrazole compounds as mineralocorticoid receptor antagonists. WO2010116282A1, 2010.
27. Casimiro-Garcia, A.; Futatsugi, K.; Piotrowski, D. W. Preparation of morpholine compounds as therapeutic mineralocorticoid receptor antagonists. WO2011141848A1, 2011.
28. Futatsugi, K.; Piotrowski, D. W.; Casimiro-Garcia, A.; Robinson, S.; Sammons, M.; Loria, P. M.; Banker, M. E.; Petersen, D. N.; Schmidt, N. J. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists Bioorg. Med. Chem. Lett. 2013, 23, 6239-6242
29. Meyers, M. J.; Arhancet, G. B.; Hockerman, S. L.; Chen, X.; Long, S. A.; Mahoney, M. W.; Rico, J. R.; Garland, D. J.; Blinn, J. R.; Collins, J. T.; Yang, S.; Huang, H.-C.; McGee, K. F.; Wendling, J. M.; Dietz, J. D.; Payne, M. A.; Homer, B. L.; Heron, M. I.; Reitz, D. B.; Hu, X. Discovery of (3 S,3a R)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2 H -benzo[ g ]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy J. Med. Chem. 2010, 53, 5979-6002
30. Orena, S.; Maurer, T. S.; She, L.; Eudy, R.; Bernardo, V.; Dash, D.; Loria, P.; Banker, M. E.; Tugnait, M.; Okerberg, C. V.; Qian, J.; Boustany-Kari, C. M. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy Front. Pharmacol. 2013, 4, 115
31. PF-03882845 was dosed as 75% spray dried dispersion (SDD) in Phase 1 clinical trial. See A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption; U.S. National Library of Medicine: Bethesda, MD, 2011; http://clinicaltrials.gov/show/NCT01366287.
32. Boos, C.; Bowles, D. M.; Cai, C.; Casimiro-Garcia, A.; Chen, X.; Hulford, C. A.; Jennings, S. M.; Kiser, E. J.; Piotrowski, D. W.; Sammons, M.; Wade, R. A. Synthesis and cross coupling of a highly substituted 2-pyridylboronate: application to the large scale synthesis of a mineralocorticoid antagonist Tetrahedron Lett. 2011, 52, 7025-7029
33. Dehring, K. A.; Workman, H. L.; Miller, K. D.; Mandagere, A.; Poole, S. K. Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility J. Pharm. Biomed. Anal. 2004, 36, 447-456
34. Hasui, T.; Matsunaga, N.; Ora, T.; Ohyabu, N.; Nishigaki, N.; Imura, Y.; Igata, Y.; Matsui, H.; Motoyaji, T.; Tanaka, T.; Habuka, N.; Sogabe, S.; Ono, M.; Siedem, C. S.; Tang, T. P.; Gauthier, C.; De, M. L. A.; Boyd, S. A.; Fukumoto, S. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists J. Med. Chem. 2011, 54, 8616-8631
35. Hasui, T.; Ohra, T.; Ohyabu, N.; Asano, K.; Matsui, H.; Mizukami, A.; Habuka, N.; Sogabe, S.; Endo, S.; Siedem, C. S.; Tang, T. P.; Gauthier, C.; De, M. L. A.; Boyd, S. A.; Fukumoto, S. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists Bioorg. Med. Chem. 2013, 21, 5983-5994
36. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
37. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47, 1750-1759
38. Small-molecule drug discovery suite 2013-3: Glide, version 6.1; Schrodinger, LLC: New York, 2013.
39. Fagart, J.; Huyet, J.; Pinon, G. M.; Rochel, M.; Mayer, C.; Rafestin-Oblin, M.-E. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension Nature Struct. Mol. Biol. 2005, 12, 554-555
40. Li, Y.; Suino, K.; Daugherty, J.; Xu, H. E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor Mol. Cell 2005, 19, 367-380
41. Bledsoe, R. K.; Madauss, K. P.; Holt, J. A.; Apolito, C. J.; Lambert, M. H.; Pearce, K. H.; Stanley, T. B.; Stewart, E. L.; Trump, R. P.; Willson, T. M.; Williams, S. P. A Ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor J. Biol. Chem. 2005, 280, 31283-31293
42. Huyet, J.; Pinon, G. M.; Fay, M. R.; Fagart, J.; Rafestin-Oblin, M.-E. Structural basis of spirolactone recognition by the mineralocorticoid receptor Mol. Pharmacol. 2007, 72, 563-571
43. Eudy, R. J.; Sahasrabudhe, V.; Sweeney, K.; Tugnait, M.; King-Ahmad, A.; Near, K.; Loria, P.; Banker, M. E.; Piotrowski, D. W.; Boustany-Kari, C. M. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism J. Transl.Med. 2011, 9, 180
44. Sanchez, J. P. An efficient synthesis and mechanism of formation of 6-acetyl-1,2-dihydro-2-oxo-3-pyridinecarboxylic acid Tetrahedron 1990, 46, 7693-7698
45. Schrödinger Release 2013-3: Maestro, version 9.6; Schrödinger, LLC: New York, 2013.
46. Schrödinger Release 2013-3: LigPrep, version 2.8; Schrödinger, LLC: New York, 2013.
47. Watts, K. S.; Dalal, P.; Murphy, R. B.; Sherman, W.; Friesner, R. A.; Shelley, J. C. ConfGen: a conformational search method for efficient generation of bioactive conformers J. Chem. Inf. Model. 2010, 50, 534-546
48. Schrödinger Release 2013-3: ConfGen, version 2.6; Schrödinger, LLC: New York, 2013.
49. Schrödinger Release 2013-3: Desmond Molecular Dynamics System, version 3.6; D. E. Shaw Research: New York, 2013.
50. Maestro-Desmond Interoperability Tools, version 3.6; Schrödinger, LLC: New York, 2013.
51. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
52. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487
53. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
54. Guo, Z.; Mohanty, U.; Noehre, J.; Sawyer, T. K.; Sherman, W.; Krilov, G. Probing the α-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis Chem. Biol. Drug Des. 2010, 75, 348-359